

STUDY PROTOCOLS

Design, recruitment and baseline characteristics of the LENS trial

The LENS Collaborative Group

Correspondence

David Preiss, LENS Central
Coordinating Office, Richard Doll
Building, Old Road Campus, Roosevelt
Drive, Oxford OX3 7LF, UK.
Email: lens@ndph.ox.ac.uk

Website: www.ctsu.ox.ac.uk/lens

Abstract

Background: Findings from cardiovascular outcome trials suggest that treatment with fenofibrate may reduce the progression of diabetic retinopathy. However, no dedicated large-scale randomised trials have yet investigated this hypothesis.

Methods: LENS is a streamlined randomised double-masked placebo-controlled trial, based in Scotland, assessing whether treatment with fenofibrate (145 mg tablet daily or, in the context of impaired renal function, on alternate days) in people with early retinopathy reduces progression to referable diabetic retinopathy (defined in NHS Scotland's Diabetic Eye Screening grading scheme as referable background or proliferative retinopathy, or referable maculopathy in either eye) or treatment with retinal laser, intravitreal injections or vitrectomy. Adults with diabetes mellitus and non-referable retinopathy (mild background retinopathy in both eyes or observable background retinopathy in one/both eyes at the most recent NHS retinal screening assessment; or observable maculopathy in one/both eyes in the previous 3 years) were eligible. Potential participants were identified from routinely collected healthcare data and followed up using regular contact from the research team and linkage to national electronic morbidity, mortality, biochemistry and retinal screening records. Study treatment was mailed to participants.

Results: Between 18 September 2018 and 27 July 2021, 1151 participants were randomised. Their mean age was 61 (SD 12) years, 312 (27%) were female and 305 (26%) had type 1 diabetes. 96% had bilateral mild background retinopathy and 10% had observable maculopathy.

Conclusions: LENS will provide a robust evaluation of the efficacy of treating people at risk of progression of diabetic retinopathy with fenofibrate. Results are anticipated in mid-2024.

Trial Registrations: NCT03439345; ISRCTN15073006; EuDRACT 2016-002656-24.

KEYWORDS

diabetic retinopathy, fenofibrate, randomised trial

The members of the Writing Committee are listed in Appendix A.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2024 The Authors. *Diabetic Medicine* published by John Wiley & Sons Ltd on behalf of Diabetes UK.

1 | INTRODUCTION

Diabetic retinopathy (DR) is a common progressive microvascular complication of diabetes mellitus and a leading cause of visual loss,¹ one of the most feared complications of diabetes.² Non-proliferative disease is characterised by changes in the retina including microaneurysms, dot and blot haemorrhages, exudates, cotton wool spots, venous changes and intraretinal microvascular abnormalities. Progression to proliferative disease may cause complications including vitreous haemorrhage, retinal detachment and neovascular glaucoma, resulting in visual impairment. Diabetic maculopathy is characterised by microaneurysms, exudates and/or haemorrhages within the macula, which may progress to macular oedema and also threaten vision.

Key risk factors for the progression of DR include longer duration of diabetes, higher HbA1c and hypertension.³ There are few effective options to slow the progression of DR. Lowering blood pressure modestly reduces the progression of DR.⁴ Landmark trials conducted before 2000 also showed that moderately good glycaemic control substantially reduced DR complications compared with poor glycaemic control.^{5,6} However, more recent trials comparing intensive with less intensive glucose-control yielded only modest benefit.⁷ Treatments for sight-threatening disease, such as retinal laser and intravitreal injections, are expensive, associated with various risks and not effective in every patient. Therapies that are beneficial earlier in the disease and are more cost-effective are therefore needed to reduce the chances of people with diabetes developing progressive DR.

Fenofibrate is a peroxisome proliferator-activated receptor alpha agonist that reduces circulating triglycerides and LDL-cholesterol and increases HDL cholesterol.⁸ Two randomised placebo-controlled cardiovascular outcome trials of fenofibrate therapy, conducted in participants with type 2 diabetes, have reported on DR outcomes. In the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, adjudicated reports of retinal laser therapy, a tertiary outcome, were proportionally reduced by 31% (164 first events in 4895 [3.4%] participants on fenofibrate vs. 238 first events in 4900 [4.9%] participants on placebo^{9,10}). The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid study was conducted in 5518 participants on background open-label simvastatin.¹¹ 1593 ACCORD Lipid participants joined the ACCORD Eye sub-study, which included two standardised eye examinations and fundal photography at baseline and 4 years.¹² The composite outcome of laser treatment, vitrectomy or 3-step progression on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale was proportionally reduced by 40%

Novelty statement

What Is Already Known?

- Diabetic retinopathy remains a leading cause of visual loss.
- Results from cardiovascular trials of fenofibrate suggest that treatment with the lipid-modifying drug fenofibrate may reduce the progression of diabetic retinopathy. However, no dedicated large-scale trials have yet been conducted to confirm this.

What this Study Adds?

- LENS is a streamlined double-masked randomised placebo-controlled trial, embedded within routine care, designed to assess the effect of treatment with fenofibrate in people with early diabetic retinopathy on a composite primary outcome of progression to referable diabetic retinopathy or the need for treatment with intravitreal injections, retinal laser or vitrectomy.

(52 first events in 806 (6.5%) participants on fenofibrate vs. 80 first events in 787 (10.2%) participants on placebo).

Although promising, these results should be considered hypothesis-generating because they are derived from analyses of non-primary trial outcomes in null cardiovascular trials and do not take account of multiple statistical testing. There is therefore a pressing need for trials designed with the primary intention of investigating the effect of fenofibrate on the progression of DR. The Lowering Events in Non-proliferative retinopathy in Scotland (LENS) trial is designed to achieve this objective, making use of existing healthcare data to recruit and follow participants. In this manuscript, we describe the design, recruitment and baseline characteristics of the LENS trial.

2 | MATERIALS AND METHODS

2.1 | Trial organisation

LENS was designed by investigators based at the trial's Central Coordinating Office (CCO) at the Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford. It is run by the Trial Management Group at the CCO who work closely with the Regional Coordinating

Centre at NHS Greater Glasgow and Clyde to guide activities at sites within all 11 mainland NHS Scotland Health Boards. The trial has oversight from a majority independent Trial Steering Committee (TSC), constituted from clinical experts and patient representatives. An independent Data Monitoring Committee (DMC) is responsible for reviewing unmasked data every 6 months to assess participant safety and trial progress, and for making recommendations to the TSC. The University of Oxford is the trial sponsor.

2.2 | Aims

The LENS trial set out to randomise participants with non-referable DR to fenofibrate or placebo to assess its effect on time to the primary composite outcome of progression to referable DR or treatment for DR. Referable DR is defined as referable background (sometimes called severe non-proliferative) DR or proliferative DR or referable maculopathy in either eye (Table 1). Referable DR in the trial is typically identified during NHS retinal screening but may also be identified from adverse event reports. Treatment for DR includes retinal laser therapy, intravitreal injection and vitrectomy. Analyses of change in visual acuity, visual function, quality of life and health economics are also planned along with other pre-specified eye outcomes. The primary, secondary and tertiary outcomes are listed in Table 2.

The design of LENS is streamlined and heavily embedded within routine clinical care. Data collection consists of participant-reported information being recorded directly into a bespoke web-based system during study assessments alongside regular linkage to NHS Scotland healthcare datasets. The protocol is included in the supplementary materials and the design is summarised in Figure 1.

2.3 | Retinal screening in Scotland

Retinal screening in Scotland is routinely offered to people with diabetes. Single 45-degree retinal photographs of each eye showing the macula and optic disc are taken through an undilated pupil. Mydriatic eye drops are used if undilated images are inadequate. When adequate images are still not obtained, slit lamp examination is arranged. Retinal images are graded according to the NHS Scotland Diabetic Eye Screening (DES) scheme (Table 1) and undergo three levels of grading—Level 1 (typically conducted using image analysis software) to identify images with retinal disease, Level 2 (by junior graders) to identify images with potentially sight-threatening disease and Level 3 (by senior graders) to make the final decision

regarding which patients require specialist referral or further investigation. Graders participate in an annual external quality assurance programme.

2.4 | Healthcare datasets in Scotland

The Community Health Index (CHI) number is a unique 10-character numeric identifier allocated to each NHS Scotland patient. This allows linkage to healthcare datasets including:

- *Diabetic Eye Screening (DES)*: retinal images and results from retinal screening records
- *Scottish Care Information—Diabetes (SCI Diabetes)*: integrated electronic patient record used in general practice and hospitals to support treatment of diabetes, including biochemistry and retinal screening data
- *National Records of Scotland (NRS) death registrations*
- *Prescribing Information System (PIS)*: data regarding medicines prescribed in the community
- *General Acute Inpatient and Day Case—Scottish Morbidity Record (SMR01)*: data regarding hospitalisations (for health economic analyses)
- *Outpatient Appointments and Attendances—Scottish Morbidity Record (SMR00)*: data for outpatient hospital appointments (for health economic analyses)

2.5 | Eligibility

Consenting adults with diabetes mellitus (other than gestational diabetes) and non-referable DR were potentially eligible to join the trial. Non-referable DR is defined as: (a) mild background DR (R1) in both eyes or observable background DR (R2) in one/both eyes at the most recent NHS retinal screening assessment, or (b) observable maculopathy (M1) in one/both eyes at an NHS retinal screening assessment in the last 3 years (Table 1; it should be noted that participants were invited based on non-referable DR at their most recent retinal screening and not earlier retinal screening results). We excluded patients with no DR or only unilateral mild background DR as they are at low risk of progression to referable DR¹³ (having, respectively, approximately 15-fold and 4-fold lower risks than the trial's target population based on DES data (available in the protocol)). Hepatobiliary diseases, renal replacement therapy, previous organ transplant, significant muscle disease, pregnancy, breastfeeding and the use of certain medications were the other main exclusion criteria. Selected biochemical tests were also conducted at screening and randomisation assessments to confirm eligibility. Estimated glomerular function rate (eGFR) was required

TABLE 1 Scottish Diabetic Eye Screening grading scheme for diabetic retinopathy.

Grading	Description	Findings	Outcome
RETINOPATHY (excluding the macula)			
R0	No DR anywhere	–	Rescreen in 12–24 months
R1	Mild background diabetic retinopathy	The presence of at least one of any of the following features anywhere: <ul style="list-style-type: none"> • Dot haemorrhages/microaneurysms • Hard exudates • Cotton wool spots • Blot haemorrhages^a • Superficial/ flame-shaped haemorrhages 	Rescreen in 12 months
R2	Observable background diabetic retinopathy	Four or more blot haemorrhages ^a in one hemifield only (Inferior and superior hemifields delineated by a line passing through the centre of the fovea and optic disc)	Rescreen in 6 months
R3	Referable background diabetic retinopathy	Any of the following features: <ul style="list-style-type: none"> • Four or more blot haemorrhages^a in both inferior and superior hemifields • Venous beading • Intraretinal Microvascular Abnormalities (IRMA) 	Specialist referral (routine)
R4	Proliferative diabetic retinopathy	Any of the following features: <ul style="list-style-type: none"> • Active new vessels • Vitreous haemorrhage 	Specialist referral (urgent)
R4i ^b	Treated proliferative diabetic retinopathy	Any of the following features: <ul style="list-style-type: none"> • Inactive new vessels with evidence of laser treatment 	Rescreen in 12 months
R6	Not adequately visualised	Retina not sufficiently visible for assessment	Technical failure
Maculopathy			
M0	No maculopathy	No features ≤ 2 disc diameters from the centre of the fovea sufficient to qualify for M1 or M2	Rescreen in 12–24 months
M1	Observable maculopathy	Lesions as specified below within a radius of >1 but ≤ 2 disc diameters from the centre of the fovea: <ul style="list-style-type: none"> • Any hard exudates 	Rescreen in 12 months
M2 ^c	Referable maculopathy	Lesions as specified below within a radius of ≤ 1 disc diameter of the centre of the fovea: <ul style="list-style-type: none"> • Any blot haemorrhages^a • Any hard exudates 	OCT surveillance scan or Rescreen in 12 months

^aBlot haemorrhage has the same or greater diameter as a retinal vein crossing the optic disc.

^bR4i is not counted towards the primary outcome as it represents inactive disease.

^cAt the start of LENS in 2018 and until end-2021, all M2 results led to specialist ophthalmology referral. In 2022, DES started to introduce a phased change to the management pathway of patients with M2 disease. In the new pathway, patients graded M2 with poor visual acuity (Snellen 6/9.5 or worse) are referred for optical coherence tomography (OCT) imaging. If this shows central referable macular oedema, the patient is referred to an ophthalmologist, with medical retina expertise for further assessment and treatment. Patients who do not require OCT, or in whom there is no evidence of central referable macular oedema on OCT, are not automatically referred to a specialist. Given that M2 (or equivalent disease) requires specialist referral/review in many countries, LENS continued to categorise M2 as referable maculopathy after this change.

to be ≥ 40 mL/min/1.73 m² at screening and ≥ 30 mL/min/1.73 m² at the randomisation assessment to allow for the expected increase in serum creatinine on fenofibrate during the active run-in.^{14,15} There were no limits on lipids, HbA1c or blood pressure to enter the trial. Table 3 provides the full eligibility criteria.

2.6 | Invitation, pre-screening, screening, run-in and randomisation

- *Invitation:* with appropriate approvals, SCI Diabetes staff performed searches to identify adults in mainland Scotland with diabetes who had non-referable DR at

TABLE 2 Primary and secondary outcomes for the LENS trial.

Primary outcome

- A composite of the development of referable diabetic retinopathy (defined as referable background retinopathy or proliferative retinopathy or referable maculopathy in either eye) or treatment for diabetic retinopathy (including retinal laser therapy, vitrectomy or intravitreal injection of medication)

Secondary outcomes

- The composite primary outcome in various subgroups:
 - Sex (men vs. women)
 - Age (<60 years vs. ≥60 years)
 - Type of diabetes (type 1 diabetes vs. type 2 diabetes and other types).
 - Renal function (randomisation eGFR <60 vs. ≥60 mL/min/1.73m²).
 - HbA1c <70 mmol/mol (8.6%) vs. ≥70 mmol/mol (8.6%).
 - First primary outcome in the first year vs. subsequent years of follow-up.
- The individual components of the composite primary outcome, namely:
 - The development of referable diabetic retinopathy
 - Treatment for diabetic retinopathy: any of retinal laser therapy, vitrectomy or intravitreal injection
- Any progression of diabetic retinopathy
- The presence of hard exudates or blot haemorrhages within 1 disc diameter of the macula
- Macular oedema^a
- Change in visual function
- Change in quality of life
- Change in visual acuity
- Health economic assessments

Tertiary outcomes

- Change in urine albumin: creatinine ratio
- Major cardiovascular events (composite of myocardial infarction, stroke, coronary and peripheral arterial revascularisation)
- Non-traumatic lower limb amputations

^aBased on (i) any finding of macular oedema during OCT imaging as part of the DES retinal screening programme, and (ii) adjudicated adverse event reports of macular oedema.

their most recent retinal screening and eGFR ≥40 mL/min/1.73 m² (but not other eligibility criteria). These lists were provided securely to NHS Scotland Health Boards for approval, following which they were sent to the Health Informatics Centre (HIC), University of Dundee. HIC mailed invitation letters (including a Participant Information Leaflet and reply slip) to potentially eligible individuals.

- *Pre-screening*: Study site staff used available medical records to perform pre-screening for interested respondents based on retinal screening results, renal function and any other obvious exclusion criteria.
- *Screening assessment*: At this in-person visit, information regarding eligibility, other relevant clinical information

and contraindicated medications was recorded and informed consent was obtained. Participants completed Quality of Life (EQ-5D-5L) and Visual Function (VFQ-25) questionnaires on paper. Samples were sent to local NHS biochemistry laboratories for analyses of renal function, liver function tests, creatine kinase, HbA1c, random lipid profile and urine albumin: creatinine ratio.

- *Active run-in*: Site investigators (or delegated study doctors) electronically approved eligible participants' entry into an active run-in phase. Participants were then mailed a 10-week supply of open-label nanoparticle fenofibrate 145 mg tablets. Those with screening eGFR ≥60 mL/min/1.73 m² were instructed to take one tablet daily and those with eGFR 40–59 mL/min/1.73 m² to take one tablet on alternate days.
- *Randomisation assessment*: Participants were seen in person approximately 8 weeks later. Compliance with the run-in treatment, concomitant medications and adverse events during run-in were documented. Participants who reported poor compliance (i.e. taking fewer than five tablets per week for those assigned daily treatment and taking less than five tablets every 2 weeks for those assigned alternate day treatment) were excluded. Height, weight, pulse rate and blood pressure were recorded. For eligible participants who were willing to proceed, a blood sample was taken to measure renal function, liver function tests and creatine kinase. When sites were temporarily closed due to the COVID-19 pandemic, site staff were permitted to perform randomisation assessments by telephone; however, blood results were still required to fully assess eligibility and samples were collected at the soonest opportunity.
- *Randomisation*: A web-based minimisation algorithm was used to randomise participants in a 1:1 ratio between fenofibrate and placebo. Minimisation criteria (listed in the protocol) were selected to balance prognostically important variables.¹⁶ The randomisation algorithm also contained a stochastic element, with simple randomisation used 10% of the time.
- *Follow-up*: Trial-specific questionnaires were administered by telephone approximately every 6 months to obtain information about adverse events leading to the cessation of study treatment, all serious adverse events, eye outcome events and the use of contraindicated medications. There was an option for follow-up via medical record review if a participant could not be contacted or no longer wished to be contacted. Paper EQ-5D-5L and VFQ-25 questionnaires were mailed to participants for completion 2 years after randomisation and at the end of the trial. Participants continuing study treatment were regularly mailed 26-week




FIGURE 1 Design of the LENS trial.

*One tablet daily if eGFR ≥ 60 mL/min/1.73 m², one tablet on alternate days if 40–59 mL/min/1.73 m²; [†]One tablet daily if eGFR ≥ 60 mL/min/1.73 m², one tablet on alternate days if 30–59 mL/min/1.73 m²; [‡]Defined as retinal laser, intravitreal injection or vitrectomy for diabetic eye disease.

supplies of nanoparticle fenofibrate 145 mg or placebo. The appropriate dose of fenofibrate depended on renal function. Those with a randomisation assessment eGFR ≥ 60 mL/min/1.73 m² were commenced on one tablet daily and those with eGFR 30–59 mL/min/1.73 m² on one tablet on alternate days. Because no face-to-face follow-up study visits were conducted after randomisation during the trial, eGFR results were monitored remotely using blood results from routine care (noting that $>90\%$ of patients with diabetes in Scotland have their renal function checked every 15 months¹⁷). A study doctor at the Regional Coordinating Centre performed monthly automated searches of SCI Diabetes to identify participants with post-randomisation eGFR falling to 30–59 mL/min/1.73 m² (study drug was then reduced to one tablet on alternate days) or to <30 mL/min/1.73 m² (study treatment was then stopped but could be restarted if renal function improved). Linkages to healthcare datasets were performed regularly including DES and SCI Diabetes (to identify pre-specified DR outcomes), and to SMR01, SMR00, PIS and the NRS death registry.

- **Adjudication:** Adverse event reports of eye procedures, vitreous haemorrhages and macular oedema were adjudicated by experienced doctors at the CCO, masked to treatment allocation.

2.7 | Statistical considerations

DES data suggested that progression from non-referable to referable DR in the target population would occur

in approximately 29% of patients over 4 years. We calculated that a sample size of 1060 participants would provide 85% power (at 2-sided $p < 0.05$) to detect a 33% reduction in the primary outcome, based on 222 first events occurring over an expected average follow-up period of 4 years (allowing for 15% drop-out, e.g. no longer attending retinal screening). The trial was therefore designed to continue until two conditions were met: (i) the occurrence of at least 222 primary outcome events; and (ii) at least 4 years to have elapsed from randomisation of the median participant. No formal interim analyses were planned for early stopping due to efficacy. The statistical analysis plan is included in the supplementary materials.

3 | RESULTS

3.1 | Recruitment

In total, 17,129 individuals were invited to participate across mainland Scotland. Of them, 3981 (23.2%) responded positively and were pre-screened with 2348 excluded before screening (655 due to ineligible retinal screening results, 24 due to low eGFR, 480 who were no longer interested when contacted, 1153 who were ineligible for other reasons and 36 who were eligible but did not attend the screening visit). In total, 1633 attended a trial screening assessment. Of them, 1484 entered the active run-in phase and 149 did not (117 failed the eligibility criteria, 2 declined to give consent, 13 withdrew during screening and 17 were not approved to enter the run-in

TABLE 3 Inclusion and exclusion criteria for entry into the LENS trial.**Inclusion criteria**

All of the following criteria must be fulfilled:

1. Subjects capable of giving informed consent
2. Diabetes Mellitus (any type except gestational diabetes)
3. Age ≥ 18 years
4. Non-referable diabetic retinopathy (defined according to NHS Scotland's Diabetic Eye Screening grading scheme as mild background retinopathy (R1) in both eyes or observable background retinopathy (R2) in one/both eyes at the most recent NHS retinal screening assessment; or observable maculopathy (M1) in one/both eyes at any NHS retinal screening assessment in the last 3 years)
5. Willing to either complete electronic questionnaires or conduct telephone interviews for collection of questionnaire data once every 6 months

Exclusion criteria

None of the following criteria must be fulfilled:

1. Referable diabetic retinopathy (defined by NHS Scotland's Diabetic Eye Screening grading scheme as referable background retinopathy (R3) or proliferative retinopathy (R4) or referable maculopathy (M2) in either eye)
2. History of gallbladder disease (cholecystitis, symptomatic gallstones, cholecystectomy)
3. History of acute or chronic pancreatitis
4. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) $>2X$ the upper limit of normal (ULN) at screening visit; ALT or AST $>2.5X$ ULN at randomisation visit
5. Creatine kinase (CK) $>3X$ ULN at screening visit; CK $>3X$ ULN at randomisation visit
6. Estimated glomerular filtration rate (eGFR) <40 mL/min/1.73m² at screening visit; eGFR <30 mL/min/1.73m² at randomisation visit
7. Cirrhosis of any aetiology or any other serious hepatic disease
8. Female who is pregnant, breastfeeding, currently trying to become pregnant or of child-bearing potential and not practising birth control
9. Ongoing vitamin K antagonist (warfarin, phenindione, acenocoumarol), cyclosporine, colchicine, ketoprofen, daptomycin, fibrate therapy or treatment with rosuvastatin 40mg daily
10. Previous myositis, myopathy or rhabdomyolysis of any cause or diagnosed hereditary muscle disorder
11. Ongoing renal replacement therapy
12. Any previous organ transplant
13. Previous reported intolerance to any fibrate
14. Medical history that might limit the individual's ability to take trial treatments for the duration of the study (e.g. severe respiratory disease, history of cancer within last 5 years other than non-melanoma skin cancer; or recent history of alcohol or substance misuse)
15. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the trial or may influence the result of the trial, or the participant's ability to participate in the trial
16. Participation in any other study or trial that excludes co-enrolment or if the intervention being investigated in another trial has the potential to interact with fenofibrate therapy
17. Not adherent to active run-in treatment

phase by the site investigator). A further 189 participants withdrew during the run-in period. Of the 1295 participants who attended a randomisation assessment, 144 were ineligible (107 failed the eligibility criteria and 37 were withdrawn after the randomisation assessment but before randomisation, typically based on new retinal screening results). From 18 September 2018 to 27 July 2021, 1151 participants were randomised (Figure 2).

3.2 | Characteristics of 1151 randomised LENS participants

The mean (standard deviation) age was 60.7 (12.3) years and 839 (73%) were men. There were 305 (26%) participants with type 1 diabetes. Mean total cholesterol was 4.0 (1.0) mmol/L and 854 (74%) were on statin therapy. Mean HbA1c was 66 (16) mmol/mol (8.2 (1.5) %) and participants had a long duration of diabetes (18 (10) years). The substantial majority (96%) had bilateral mild background DR (R1), and 10% had observable maculopathy (M1) in at least one eye at their most recent retinal screening visit. Serum creatinine rose from the screening assessment to the randomisation assessment due to the known effect of fenofibrate. As a consequence, the proportion of those with eGFR <60 mL/min/1.73 m² increased from 9% at the screening assessment to 23% at the randomisation assessment (Table 4).

To assess the representativeness of LENS participants, SCI Diabetes data were used to compare them to the potentially eligible population in Scotland. This was achieved by repeating the SCI Diabetes recruitment search (based on age ≥ 18 years, non-referable DR and eGFR (as used to determine LENS eligibility)) in August 2023. Participants recruited into LENS were broadly representative of the population of patients in Scotland, identified as potentially eligible for the trial, with respect to important risk factors for DR progression including age, type of diabetes, HbA1c, DR grading and eGFR (Table 5). The proportions of women and individuals of non-White ethnicity were lower in LENS than in the potentially eligible population. Based on the Scottish Index of Multiple Deprivation (SIMD), a measure of social deprivation based on home address postcode,¹⁸ trial participants were modestly less socially deprived than the target population.

3.3 | COVID-19 and retinal screening

The COVID-19 pandemic led to a temporary cessation of the national retinal screening programme in April 2020. When NHS Scotland restarted retinal screening, it was




FIGURE 2 Trial profile—flow of participants through LENS trial recruitment.

necessary to apply new procedures for cleaning equipment and spacing, thereby slowing the throughput for retinal screening for a period of time. However, activity has subsequently increased and retinal screening activity in LENS participants has returned to full capacity.

3.4 | Follow-up

The median participant was randomised on 16 July 2019. Given that masked assessments showed that the primary outcome event rate was at least as high as assumed in the sample size calculation (despite the COVID-19 pandemic), final follow-up assessments commenced on 17 July 2023. Final follow-up assessments and final data linkages occurred in late 2023.

4 | DISCUSSION

The LENS trial is designed to assess the efficacy of treatment with fenofibrate for slowing the progression of DR in 1151 people with diabetes and non-referable DR, using a streamlined design. The trial is heavily embedded within routine NHS care and uses retinal screening results (to both invite potentially eligible patients and identify pre-specified DR outcomes) and regular telephone calls to participants to record clinical events of interest.

Large placebo-controlled cardiovascular outcome trials of fenofibrate have suggested that treatment for 4–5 years may substantially reduce the progression of DR.^{9,10,12} We designed LENS to investigate this hypothesis, using nanoparticle fenofibrate, a formulation not influenced by food intake.¹⁹ Other trials, namely FAME-1-EYE

TABLE 4 Baseline characteristics of LENS participants.

	Overall (N = 1151)	
Demographics		
Age at randomisation (years)	60.7	(12.3)
Sex		
Male	839	(73%)
Female	312	(27%)
Ethnicity		
White	1125	(98%)
Other	26	(2%)
Prior disease		
Type of diabetes mellitus		
Type 1	305	(26%)
Type 2	844	(73%)
Other	2	(0%)
Duration of diabetes (years)	18.0	(10.3)
Retinopathy grading (worse eye) ^a		
No retinopathy (R0)	9	(1%)
Mild background retinopathy (R1)	1126	(98%)
Observable background retinopathy (R2)	16	(1%)
Maculopathy grading (worse eye) ^{a,b}		
No maculopathy (M0)	1032	(90%)
Observable diabetic maculopathy (M1)	119	(10%)
Clinical measurements		
Systolic blood pressure (mmHg) ^e	136.6	(17.5)
Diastolic blood pressure (mmHg) ^e	75.5	(9.4)
Body mass index (kg/m ²) ^e	30.8	(6.2)
Laboratory measurements		
HbA1c (mmol/mol) ^e	66	(16)
HbA1c (%) ^e	8.2	(1.5)
Total cholesterol (mmol/L) ^e	4.0	(1.0)
HDL cholesterol (mmol/L) ^e	1.3	(0.4)
Triglycerides (mmol/L) ^{c,e}	1.5	(1.1–2.3)
Serum Creatinine (umol/L) ^d		
Screening assessment	77.9	(18.5)
Randomisation assessment	89.1	(22.3)
eGFR (mL/min/1.73m ²) ^d		
Screening assessment		
<60	98	(9%)
≥60	1053	(91%)
Randomisation assessment		
<60	261	(23%)
≥60	890	(77%)

TABLE 4 (Continued)

	Overall (N = 1151)	
Concomitant medications		
Non-insulin glucose-lowering therapy	785	(68%)
Insulin	505	(44%)
Statin	854	(74%)
Renin-angiotensin system inhibitor	686	(60%)

Note: Results are shown as N (%) or mean (standard deviation) unless otherwise indicated.

^aWorse eye retinopathy defined as R2 > R1 > R0; worse eye maculopathy defined as M1 > M0.

^b16 participants had bilateral M0 and either bilateral R0 or R1/R0 at their most recent retinal screening prior to randomisation, and therefore qualified based on M1 from an earlier retinal screening visit within the last 3 years.

^cMedian (IQR).

^dFenofibrate therapy is known to reversibly increase serum creatinine and reduce eGFR.

^eMissing data: systolic and diastolic blood pressure 70 participants, BMI 35 participants, HbA1c 74 participants, total cholesterol 12 participants, HDL cholesterol 23 participants, triglycerides 17 participants (no missing data for other variables).

(recruiting participants with type 1 diabetes and non-proliferative DR; NCT01320345) and Fenofibrate for Prevention of DR Worsening (recruiting participants with non-proliferative DR; NCT04661358) are also investigating the effect of fenofibrate on DR for which there is accumulating evidence of a direct effect on the retina.²⁰ Unlike LENS, which links to NHS Scotland's retinal screening programme, these two trials use ETDRS-graded retinal images collected at set time points for their main outcomes. LENS participants were asked for consent for their retinal screening images to be securely stored in an imaging biobank at the CCO, University of Oxford, for subsequent research. Approximately 9000 images from 4000 retinal screening episodes had been received as of July 2023. This will facilitate grading using other systems and, therefore, pooling of data with other fenofibrate trials in the future.

Comparison of LENS trial participants with all potentially eligible participants (based on recent retinal screening and eGFR ≥40 mL/min/1.73 m²) in mainland Scotland shows that they are highly representative with respect to important risk factors for progressive DR. For example, over a quarter of participants have type 1 diabetes, in keeping with the high risk of incident and progressive DR in such individuals. However, 27% of LENS participants are women, compared with 39% of potentially eligible participants. There are two likely contributors. First, the LENS Participant Information Leaflet stressed the lack of safety information in pregnancy and breastfeeding and explained that pre-menopausal women must use reliable contraception. This is likely to have dissuaded some

TABLE 5 Representativeness of LENS trial participants.

<i>N</i>	Potentially eligible people ^a		LENS participants	
	31,118		1151	
Age at randomisation (years)	60.5	(15.3)	60.7	(12.3)
Sex				
Male	18,958	(61%)	839	(73%)
Female	12,160	(39%)	312	(27%)
Ethnicity ^b				
White	24,001	(91%)	1125	(98%)
Other	2475	(9%)	26	(2%)
Scottish Index of Multiple Deprivation ^c	2.8	(1.4)	3.0	(1.4)
Prior disease				
Type of diabetes mellitus				
Type 1	8232	(27%)	305	(26%)
Type 2 or other	22,886	(74%)	846	(74%)
Retinopathy grading (worse eye) ^d				
No retinopathy (R0)	35	(0%)	9	(1%)
Mild background retinopathy (R1)	29,964	(96%)	1126	(98%)
Observable background retinopathy (R2)	1119	(4%)	16	(1%)
Maculopathy grading (worse eye) ^d				
No maculopathy (M0)	26,779	(86%)	1032	(90%)
Observable diabetic maculopathy (M1)	4339	(14%)	119	(10%)
HbA1c (mmol/mol)	68	(18)	66	(16)
HbA1c (%)	8.4	(1.7)	8.2	(1.5)
eGFR (mL/min/1.73 m ²)				
<60	4019	(13%)	98	(9%)
≥60	27,099	(87%)	1053	(91%)

Note: Results are shown as *N* (%) or mean (standard deviation).

^aBased on SCI Diabetes search for summary data regarding patients with (i) non-referable retinopathy at most recent retinal screening, and (ii) eGFR ≥40 mL/min/1.73 m² at their most recent blood test.

^bEthnicity for potentially eligible individuals based on 26,476 (85% of total) with available information.

^cBased on quintiles of SIMD (calculated based on seven domains: income, employment, education, health, access to services, crime and housing).

^dWorse eye retinopathy defined as R2 > R1 > R0, worse eye maculopathy defined as M1 > M0.

women from joining the trial. Second, information regarding other randomised trials conducted in cardio-metabolic disease shows that women appear less likely to volunteer.²¹ Trial participants are also modestly less socially deprived, based on SIMD score, a pattern observed in other trials.²¹ The substantial majority (98%) of LENS participants are white, similar to other large diabetes trials in the UK,²² and more than the estimated proportion (approximately 91% of potentially eligible individuals with race recorded) in Scotland.¹⁷

Retinal screening programmes exist in various health-care settings. These programmes serve to identify patients with sight-threatening disease so that they can receive specialist follow-up and, if required, treatment. LENS suggests that this infrastructure also provides a useful setting to identify those at higher risk of progression at an earlier stage (if efficacious treatment options can be identified) and to conduct randomised trials. An additional advantage of conducting LENS in a country with a single provider of retinal screening is that it offers the opportunity

for prolonged post-trial follow-up and trial participants provided consent for this. The design proved to be generally robust to the impact of the COVID-19 pandemic—we were able to conduct follow-up assessments by telephone and to send study treatment to participants by mail.

In summary, LENS will provide a robust evaluation of the efficacy of fenofibrate treatment in a representative population of people with non-referable DR. Results from the trial are expected in mid-2024.

ACKNOWLEDGEMENTS

We are very grateful to all participants, staff at participating NHS Scotland sites and members of the Trial Steering Committee and Data Monitoring Committee. We greatly appreciate the support of NHS Scotland's Diabetic Eye Screening Collaborative, the Scottish Care Information Diabetes Collaboration (SCI Diabetes), Public Health Scotland's electronic Data Research and Innovation Service (eDRIS), the Health Informatics Centre at the University of Dundee and PCI Pharma Services.

FUNDING INFORMATION

LENS was primarily funded by the National Institute for Health and Care Research (NIHR), Health Technology Assessment Programme (14/49/84). The views expressed are those of the authors and not necessarily those of the NIHR or the UK's Department of Health and Social Care. The Nuffield Department of Population Health (NDPH), University of Oxford, covered the costs of storing, packaging and preparation for mailing of study treatment. LENS is coordinated by the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), NDPH, University of Oxford; CTSU receives funding from the UK Medical Research Council (MRC), the British Heart Foundation and Health Data Research (HDR) UK. During the conduct of the trial, David Preiss was also supported by a University of Oxford BHF Centre of Research Excellence Senior Transition Fellowship (RE/13/1/30181), MRC (MC_UU_12026) and HDR UK (OXFD1 & HDRUK2023.0025).

DISCLOSURES

CTSU at the University of Oxford has a staff policy of not accepting personal honoraria or consultancy fees (see <https://www.ndph.ox.ac.uk/about/independence-of-research>). Since 2022, Jennifer Logue has been an employee of AstraZeneca (which has had no role in the funding, design, delivery or results of this study) with an honorary academic appointment at Lancaster University and has received funding for conference attendance and advisory board membership from Novo Nordisk. Other authors declare no conflicts of interest. Mylan provided bulk study treatment free of charge but played no role in the design or conduct of the trial.

REFERENCES

1. GBD 2019 blindness and vision impairment collaborators and vision loss expert Group of the Global Burden of disease study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to sight: an analysis for the global burden of disease study. *Lancet Glob Health*. 2021;9(2):e144-e160.
2. Wukich DK, Raspovic KM, Suder NC. Patients with diabetic foot disease fear major lower-extremity amputation more than death. *Foot Ankle Spec*. 2018;11(1):17-21.
3. Looker HC, Nyangoma SO, Cromie DT, et al. Rates of referable eye disease in the Scottish National Diabetic Retinopathy Screening Programme. *Br J Ophthalmol*. 2014;98(6):790-795.
4. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. *Jama*. 2015;313(6):603-615.
5. Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med*. 1993;329(14):977-986.
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet*. 1998;352(9131):837-853.
7. Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. *Lancet Diabetes Endocrinol*. 2017;5(6):431-437.
8. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. *Circulation*. 1998;98(19):2088-2093.
9. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. *Lancet*. 2007;370(9600):1687-1697.
10. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *Lancet*. 2005;366(9500):1849-1861.
11. ACCORD Study Group, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med*. 2010;362(17):1563-1574.
12. ACCORD Study Group, ACCORD Eye Study Group, Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. *N Engl J Med*. 2010;363(3):233-244.
13. Stratton IM, Aldington SJ, Taylor DJ, Adler AI, Scanlon PH. A simple risk stratification for time to development of sight-threatening diabetic retinopathy. *Diabetes Care*. 2013;36(3):580-585.
14. Davis TM, Ting R, Best JD, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the fenofibrate intervention and event lowering in diabetes (FIELD) study. *Diabetologia*. 2011;54(2):280-290.
15. Mychaleckyj JC, Craven T, Nayak U, et al. Reversibility of fenofibrate therapy-induced renal function impairment

- in ACCORD type 2 diabetic participants. *Diabetes Care*. 2012;35(5):1008-1014.
16. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. *Biometrics*. 1975;31(1):103-115.
 17. NHS Scotland. Scottish Diabetes Survey. 2021 <https://www.diabetesinscotland.org.uk/wp-content/uploads/2023/02/Diabetes-Scottish-Diabetes-Survey-2021-final-version.pdf>
 18. Scottish Government. Index of Multiple Deprivation 2020. 2020. <https://www.gov.scot/collections/scottish-index-of-multi-ple-deprivation-2020/>
 19. Sauron R, Wilkins M, Jessent V, Dubois A, Maillot C, Weil A. Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation. *Int J Clin Pharmacol Ther*. 2006;44(2):64-70.
 20. Chen Y, Hu Y, Lin M, et al. Therapeutic effects of PPARalpha agonists on diabetic retinopathy in type 1 diabetes models. *Diabetes*. 2013;62(1):261-272.
 21. Aung T, Haynes R, Barton J, et al. Cost-effective recruitment methods for a large randomised trial in people with diabetes: a study of cardiovascular events in diabetes (ASCEND). *Trials*. 2016;17(1):286.
 22. ASCEND Study Collaborative Group, Bowman L, Mafham M, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. *N Engl J Med*. 2018;379(16):1529-1539.


SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: . Design, recruitment and baseline characteristics of the LENS trial. *Diabet Med*. 2024;00:e15310. doi:[10.1111/dme.15310](https://doi.org/10.1111/dme.15310)

APPENDIX A

The LENS Collaborative Group

Writing Committee: David Preiss^{1,2}, Jennifer Logue³, Emily Sammons^{1,2}, Mohammed Zayed¹ , Jon Emberson^{1,2}, Rachel Wade¹, Karl Wallendszus¹, Will Stevens¹, Simon Harding⁴, Graham Leese⁵, Gemma Currie⁶, Jane Armitage^{1,2}

Writing Committee Affiliations: ¹Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford; ²Medical Research Council Population Health Research Unit at the University of Oxford; ³Faculty of Health and Medicine, University of Lancaster, Lancaster; ⁴Department of Eye and Vision Science, University of Liverpool and St. Paul's Eye Unit, Liverpool University

Hospitals NHS Foundation Trust, Liverpool; ⁵Molecular and Clinical Medicine, University of Dundee, Dundee; ⁶School of Cardiovascular & Metabolic Health, University of Glasgow, Glasgow

Collaborators:

Paula Williamson, Jonathan Bodansky, Allan Cairns, Sue Dickie, Gillian Hallard, Gozie Joe Adigwe, Laura Jones, Timothy Lyons, Isla Mackenzie, Dermot Neely, Sarah Wild, Ian Young, Praveen Patel, Alan Watkins, Natalie Staplin, Sarah Howard, Kate Sawyer, Karen Taylor, Patricia Achiri, Andy Burke, Susan Fathers, Susan Hurley, Gareth McChlery, Kevin Murphy, Sandra Pickworth, Alison Timadger, Kate Vandenberg, Monique Willett, Liz Wincott, Matthew Beesley, Charles Cutting, Monica Raj, Ian Roure, Michelle Goonasekera, Graham Bagley, Anne Whitehouse, Isobel Young, Gavin Brown, Kate Bird, Rosanna Cretney, Heather Halls, Guanguo Cui, Charles Daniels, Angela Field, Bob Goodenough, Youcef Mostafi, Samee Syed, Angela Chamberlain, Carol Knott, Anna Liew, Juliette Meek, Meera Mistry, Andrea Wilson, Patrick Zettegren, Rach AitSadi, Ian Barton, Alex Baxter, Clive Berry, Rijo Kurien, Michael Lay, Aleksandra Murawska, James Thompson, Allen Young, Enti Spata, Rachel Raff, Crispian Howard, Diann Taggart, Paul Connelly, Mohan Varikkara, Scott Blackwell, Fiona Elliott, Jacqueline Locke, Angela Sweeney, Stephen Wood, Olive Herlihy, Jeni Darling, Jill Little, Ewan Bell, Susan Boytha, Paula Neill, Caroline Styles, Andrew Blaikie, Laura Beveridge, Tina Coventry, Susan Fowler, Karen Gray, Linda Lister, Amanda McGregor, Sandra Pirie, Evgeniya Postovalova, Anna White, John Doig, Stephanie Brogan, Margie Duncan, Angela Gilmour, Lynn Ryan, Anne Todd, Lesley Whitelaw, Elaine Wilson, Sam Philip, Ann Cadzow, Sharlene Greig, Siby Joseph, Lynne Murray, Julie Toye, Sonia Zachariah, David Carty, Lindsey Bailey, Alison Begg, Katherine Brown, Charlotte Clark, Katharine Duffy, Shirley Fawcett, Adam Gill, Emma Hughes, David Jenkins, Laila Martin, Christine McAllister, Mhairi MciIntyre, Leeanne Milne, Erin Murphy, Hilary Peddie, Katharine Sharp, Susan Speirs, Joyce Thompson, Lynne Turner, Simon Hewick, Clare Bradley, Jim Finlayson, Laura O'Keeffe, Meena Viridi, Soo Park, Murdina Bell, Maureen Brown, Linda Macliver, Jackie Quigley, Karen Madill, Daniel Beck, Freddie Burgess, Karen Charlwood, Lauren Finlayson, Nicola Freeman, Margaret McDonald, Carla Pettifor, Karen Sedstrem, Alice Thomson, Ellen Malcolm, Jackie Lindsay, Lisa Stewart, Helen Colhoun, Robert Lindsay, John Olson, Naveed Sattar, Graham Scotland